首页 > 最新文献

Clinical & Translational Oncology最新文献

英文 中文
SEOM-GEM clinical guidelines for cutaneous melanoma (2023). SEOM-GEM 皮肤黑色素瘤临床指南(2023 年)。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-05-15 DOI: 10.1007/s12094-024-03497-2
Iván Márquez-Rodas, Eva Muñoz Couselo, Juan F Rodríguez Moreno, Ana Mª Arance Fernández, Miguel Ángel Berciano Guerrero, Begoña Campos Balea, Luis de la Cruz Merino, Enrique Espinosa Arranz, Almudena García Castaño, Alfonso Berrocal Jaime

Cutaneous melanoma incidence is rising. Early diagnosis and treatment administration are key for increasing the chances of survival. For patients with locoregional advanced melanoma that can be treated with complete resection, adjuvant-and more recently neoadjuvant-with targeted therapy-BRAF and MEK inhibitors-and immunotherapy-anti-PD-1-based therapies-offer opportunities to reduce the risk of relapse and distant metastases. For patients with advanced disease not amenable to radical treatment, these treatments offer an unprecedented increase in overall survival. A group of medical oncologists from the Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines, based on a thorough review of the best evidence available. The following guidelines try to cover all the aspects from the diagnosis-clinical, pathological, and molecular-staging, risk stratification, adjuvant therapy, advanced disease therapy, and survivor follow-up, including special situations, such as brain metastases, refractory disease, and treatment sequencing. We aim help clinicians in the decision-making process.

皮肤黑色素瘤的发病率正在上升。早期诊断和治疗是提高生存率的关键。对于可以通过完全切除术治疗的局部晚期黑色素瘤患者来说,采用靶向疗法--BRAF和MEK抑制剂--以及免疫疗法--抗PD-1疗法--进行辅助治疗以及最近的新辅助治疗,可以降低复发和远处转移的风险。对于无法接受根治性治疗的晚期患者来说,这些疗法能前所未有地提高总生存率。西班牙肿瘤内科学会(SEOM)和西班牙多学科黑色素瘤小组(GEM)的一组肿瘤内科医生在对现有最佳证据进行全面审查的基础上制定了这些指南。以下指南试图涵盖诊断--临床、病理和分子分期、风险分层、辅助治疗、晚期疾病治疗和幸存者随访等各个方面,包括脑转移、难治性疾病和治疗排序等特殊情况。我们旨在帮助临床医生做出决策。
{"title":"SEOM-GEM clinical guidelines for cutaneous melanoma (2023).","authors":"Iván Márquez-Rodas, Eva Muñoz Couselo, Juan F Rodríguez Moreno, Ana Mª Arance Fernández, Miguel Ángel Berciano Guerrero, Begoña Campos Balea, Luis de la Cruz Merino, Enrique Espinosa Arranz, Almudena García Castaño, Alfonso Berrocal Jaime","doi":"10.1007/s12094-024-03497-2","DOIUrl":"10.1007/s12094-024-03497-2","url":null,"abstract":"<p><p>Cutaneous melanoma incidence is rising. Early diagnosis and treatment administration are key for increasing the chances of survival. For patients with locoregional advanced melanoma that can be treated with complete resection, adjuvant-and more recently neoadjuvant-with targeted therapy-BRAF and MEK inhibitors-and immunotherapy-anti-PD-1-based therapies-offer opportunities to reduce the risk of relapse and distant metastases. For patients with advanced disease not amenable to radical treatment, these treatments offer an unprecedented increase in overall survival. A group of medical oncologists from the Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines, based on a thorough review of the best evidence available. The following guidelines try to cover all the aspects from the diagnosis-clinical, pathological, and molecular-staging, risk stratification, adjuvant therapy, advanced disease therapy, and survivor follow-up, including special situations, such as brain metastases, refractory disease, and treatment sequencing. We aim help clinicians in the decision-making process.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"2841-2855"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140923893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023). SEOM 癌症厌食-腹痛综合征临床指南(2023 年)。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-06-01 DOI: 10.1007/s12094-024-03502-8
Ainara Soria Rivas, Yolanda Escobar Álvarez, Ana Blasco Cordellat, Margarita Majem Tarruella, Kevin Molina Mata, Marta Motilla de la Cámara, Mª Del Mar Muñoz Sánchez, Marta Zafra Poves, Carmen Beato Zambrano, Luis Cabezón Gutierrez

Cancer-related anorexia-cachexia syndrome (CACS) is a debilitating condition afflicting up to 80% of advanced-stage cancer patients. Characterized by progressive weight loss, muscle wasting, and metabolic abnormalities, CACS significantly compromises patients' quality of life and treatment outcomes. This comprehensive review navigates through its intricate physiopathology, elucidating its stages and diagnostic methodologies. CACS manifests in three distinct stages: pre-cachexia, established cachexia, and refractory cachexia. Early detection is pivotal for effective intervention and is facilitated by screening tools, complemented by nutritional assessments and professional evaluations. The diagnostic process unravels the complex interplay of metabolic dysregulation and tumor-induced factors contributing to CACS. Management strategies, tailored to individual patient profiles, encompass a spectrum of nutritional interventions. These include dietary counseling, oral nutritional supplements, and, when necessary, enteral nutrition and a judicious use of parenteral nutrition. Specific recommendations for caloric intake, protein requirements, and essential nutrients address the unique challenges posed by CACS. While pharmacological agents like megestrol acetate may be considered, their use requires careful evaluation of potential risks. At its core, this review underscores the imperative for a holistic and personalized approach to managing CACS, integrating nutritional interventions and pharmacological strategies based on a nuanced understanding of patient's condition.

癌症相关厌食-痛风综合征(CACS)是一种使人衰弱的病症,多达 80% 的晚期癌症患者都会受到这种病症的困扰。CACS 的特点是进行性体重减轻、肌肉萎缩和代谢异常,严重影响患者的生活质量和治疗效果。这篇全面的综述介绍了其复杂的生理病理,阐明了其分期和诊断方法。CACS 表现为三个不同的阶段:恶病质前期、恶病质确立期和恶病质难治期。早期发现是有效干预的关键,筛查工具、营养评估和专业评价对早期发现有很大帮助。诊断过程揭示了导致 CACS 的代谢失调和肿瘤诱发因素之间复杂的相互作用。根据患者个体情况制定的管理策略包括一系列营养干预措施。其中包括饮食咨询、口服营养补充剂,必要时还包括肠内营养和慎重使用肠外营养。针对热量摄入、蛋白质需求和必需营养素的具体建议可应对 CACS 带来的独特挑战。虽然可以考虑使用醋酸甲孕酮等药物,但需要对其潜在风险进行仔细评估。本综述的核心内容是强调必须采用全面和个性化的方法来管理 CACS,在对患者病情有细致入微的了解的基础上整合营养干预和药物治疗策略。
{"title":"SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).","authors":"Ainara Soria Rivas, Yolanda Escobar Álvarez, Ana Blasco Cordellat, Margarita Majem Tarruella, Kevin Molina Mata, Marta Motilla de la Cámara, Mª Del Mar Muñoz Sánchez, Marta Zafra Poves, Carmen Beato Zambrano, Luis Cabezón Gutierrez","doi":"10.1007/s12094-024-03502-8","DOIUrl":"10.1007/s12094-024-03502-8","url":null,"abstract":"<p><p>Cancer-related anorexia-cachexia syndrome (CACS) is a debilitating condition afflicting up to 80% of advanced-stage cancer patients. Characterized by progressive weight loss, muscle wasting, and metabolic abnormalities, CACS significantly compromises patients' quality of life and treatment outcomes. This comprehensive review navigates through its intricate physiopathology, elucidating its stages and diagnostic methodologies. CACS manifests in three distinct stages: pre-cachexia, established cachexia, and refractory cachexia. Early detection is pivotal for effective intervention and is facilitated by screening tools, complemented by nutritional assessments and professional evaluations. The diagnostic process unravels the complex interplay of metabolic dysregulation and tumor-induced factors contributing to CACS. Management strategies, tailored to individual patient profiles, encompass a spectrum of nutritional interventions. These include dietary counseling, oral nutritional supplements, and, when necessary, enteral nutrition and a judicious use of parenteral nutrition. Specific recommendations for caloric intake, protein requirements, and essential nutrients address the unique challenges posed by CACS. While pharmacological agents like megestrol acetate may be considered, their use requires careful evaluation of potential risks. At its core, this review underscores the imperative for a holistic and personalized approach to managing CACS, integrating nutritional interventions and pharmacological strategies based on a nuanced understanding of patient's condition.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"2866-2876"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141187131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023). SEOM-GEMCAD-TTD 肝癌患者管理临床指南(2023 年)。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-06-24 DOI: 10.1007/s12094-024-03568-4
Carlos López López, Mariona Calvo, Juan Carlos Cámara, Beatriz García-Paredes, Carlos Gómez-Martin, Ana María López, Roberto Pazo-Cid, Javier Sastre, Ricardo Yaya, Jaime Feliu

Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child-Pugh class A.

肝细胞癌(HCC)是肝脏中最常见的原发性恶性肿瘤,也是全球癌症相关死亡的第三大原因。对于罹患 HCC 的高危人群,应通过腹部超声进行监测。在确定最佳治疗方法时,准确的诊断、分期和肝功能至关重要。BCLC 分期系统在西方国家得到广泛认可。治疗这种病变需要采取多学科、个性化的方法,通常采用多模式策略。手术仍然是唯一的治愈选择,尽管在不适合手术的情况下,局部和全身治疗也可以提高生存率。在晚期疾病中,ECOG/PS 0-1 和 Child-Pugh 分级为 A 的患者应接受系统治疗。
{"title":"SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023).","authors":"Carlos López López, Mariona Calvo, Juan Carlos Cámara, Beatriz García-Paredes, Carlos Gómez-Martin, Ana María López, Roberto Pazo-Cid, Javier Sastre, Ricardo Yaya, Jaime Feliu","doi":"10.1007/s12094-024-03568-4","DOIUrl":"10.1007/s12094-024-03568-4","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child-Pugh class A.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"2800-2811"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141447440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023). SEOM-GG 生殖细胞睾丸癌治疗临床指南(2023 年)。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-03 DOI: 10.1007/s12094-024-03532-2
José Angel Arranz Arija, Xavier García Del Muro, Raquel Luque Caro, María José Méndez-Vidal, Begoña Pérez-Valderrama, Jorge Aparicio, Miguel Ángel Climent Durán, Cristina Caballero Díaz, Ignacio Durán, Enrique González-Billalabeitia

Testicular germ cell tumors are the most common tumors in adolescent and young men. They are curable malignancies that should be treated with curative intent, minimizing acute and long-term side effects. Inguinal orchiectomy is the main diagnostic procedure, and is also curative for most localized tumors, while patients with unfavorable risk factors for recurrence, or those who are unable or unwilling to undergo close follow-up, may require adjuvant treatment. Patients with persistent markers after orchiectomy or advanced disease at diagnosis should be staged and classified according to the IGCCCG prognostic classification. BEP is the most recommended chemotherapy, but other schedules such as EP or VIP may be used to avoid bleomycin in some patients. Efforts should be made to avoid unnecessary delays and dose reductions wherever possible. Insufficient marker decline after each cycle is associated with poor prognosis. Management of residual masses after chemotherapy differs between patients with seminoma and non-seminoma tumors. Patients at high risk of relapse, those with refractory tumors, or those who relapse after chemotherapy should be managed by multidisciplinary teams in experienced centers. Salvage treatment for these patients includes conventional-dose chemotherapy (TIP) and/or high-dose chemotherapy, although the best regimen and strategy for each subgroup of patients is not yet well established. In late recurrences, early complete surgical resection should be performed when feasible. Given the high cure rate of TGCT, oncologists should work with patients to prevent and identify potential long-term side effects of the treatment. The above recommendations also apply to extragonadal retroperitoneal and mediastinal tumors.

睾丸生殖细胞瘤是青少年和年轻男性最常见的肿瘤。它们是可治愈的恶性肿瘤,治疗时应以治愈为目的,尽量减少急性和长期副作用。腹股沟睾丸切除术是主要的诊断方法,也是大多数局部肿瘤的根治方法,而有不利复发风险因素的患者,或无法或不愿接受密切随访的患者,可能需要辅助治疗。睾丸切除术后标记物持续存在或确诊时已是晚期的患者应根据 IGCCCG 预后分类进行分期和分类。BEP是最推荐的化疗方案,但也可使用其他方案,如EP或VIP,以避免某些患者使用博莱霉素。应尽可能避免不必要的延迟和剂量减少。每个周期后标记物下降不足与预后不良有关。精原细胞瘤和非精原细胞瘤患者化疗后残留肿块的处理方法有所不同。高复发风险患者、难治性肿瘤患者或化疗后复发的患者应由经验丰富的中心的多学科团队进行管理。对这些患者的挽救性治疗包括常规剂量化疗(TIP)和/或高剂量化疗,但针对每个亚组患者的最佳治疗方案和策略尚未完全确定。对于晚期复发患者,在可行的情况下应尽早进行完整的手术切除。鉴于 TGCT 的高治愈率,肿瘤学家应与患者一起预防和识别治疗可能产生的长期副作用。上述建议同样适用于对角线外腹膜后和纵隔肿瘤。
{"title":"SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023).","authors":"José Angel Arranz Arija, Xavier García Del Muro, Raquel Luque Caro, María José Méndez-Vidal, Begoña Pérez-Valderrama, Jorge Aparicio, Miguel Ángel Climent Durán, Cristina Caballero Díaz, Ignacio Durán, Enrique González-Billalabeitia","doi":"10.1007/s12094-024-03532-2","DOIUrl":"10.1007/s12094-024-03532-2","url":null,"abstract":"<p><p>Testicular germ cell tumors are the most common tumors in adolescent and young men. They are curable malignancies that should be treated with curative intent, minimizing acute and long-term side effects. Inguinal orchiectomy is the main diagnostic procedure, and is also curative for most localized tumors, while patients with unfavorable risk factors for recurrence, or those who are unable or unwilling to undergo close follow-up, may require adjuvant treatment. Patients with persistent markers after orchiectomy or advanced disease at diagnosis should be staged and classified according to the IGCCCG prognostic classification. BEP is the most recommended chemotherapy, but other schedules such as EP or VIP may be used to avoid bleomycin in some patients. Efforts should be made to avoid unnecessary delays and dose reductions wherever possible. Insufficient marker decline after each cycle is associated with poor prognosis. Management of residual masses after chemotherapy differs between patients with seminoma and non-seminoma tumors. Patients at high risk of relapse, those with refractory tumors, or those who relapse after chemotherapy should be managed by multidisciplinary teams in experienced centers. Salvage treatment for these patients includes conventional-dose chemotherapy (TIP) and/or high-dose chemotherapy, although the best regimen and strategy for each subgroup of patients is not yet well established. In late recurrences, early complete surgical resection should be performed when feasible. Given the high cure rate of TGCT, oncologists should work with patients to prevent and identify potential long-term side effects of the treatment. The above recommendations also apply to extragonadal retroperitoneal and mediastinal tumors.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"2783-2799"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023). SEOM 静脉血栓栓塞症(VTE)与癌症临床指南(2023 年)。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-08-07 DOI: 10.1007/s12094-024-03605-2
Laura Ortega Morán, Francisco José Pelegrín Mateo, Rut Porta Balanyà, Jacobo Rogado Revuelta, Silverio Ros Martínez, José Pablo Berros Fombella, Elena María Brozos Vázquez, Natalia Luque Caro, José Muñoz Langa, Mercedes Salgado Fernández

The Spanish Society of Medical Oncology (SEOM) last published clinical guidelines on venous thromboembolism (VTE) and cancer in 2019, with a partial update in 2020. In this new update to the guidelines, SEOM seeks to incorporate recent evidence, based on a critical review of the literature, to provide practical current recommendations for the prophylactic and therapeutic management of VTE in patients with cancer. Special clinical situations whose management and/or choice of currently recommended therapeutic options (low-molecular-weight heparins [LMWHs] or direct-acting oral anticoagulants [DOACs]) is controversial are included.

西班牙肿瘤内科学会(SEOM)上一次发布静脉血栓栓塞症(VTE)与癌症的临床指南是在2019年,并于2020年进行了部分更新。在此次新的指南更新中,SEOM 在对文献进行严格审查的基础上,力求纳入最新证据,为癌症患者 VTE 的预防和治疗管理提供实用的最新建议。其中包括一些特殊的临床情况,这些情况下的管理和/或对目前推荐的治疗方案(低分子量肝素 [LMWHs] 或直接作用口服抗凝剂 [DOACs])的选择存在争议。
{"title":"SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023).","authors":"Laura Ortega Morán, Francisco José Pelegrín Mateo, Rut Porta Balanyà, Jacobo Rogado Revuelta, Silverio Ros Martínez, José Pablo Berros Fombella, Elena María Brozos Vázquez, Natalia Luque Caro, José Muñoz Langa, Mercedes Salgado Fernández","doi":"10.1007/s12094-024-03605-2","DOIUrl":"10.1007/s12094-024-03605-2","url":null,"abstract":"<p><p>The Spanish Society of Medical Oncology (SEOM) last published clinical guidelines on venous thromboembolism (VTE) and cancer in 2019, with a partial update in 2020. In this new update to the guidelines, SEOM seeks to incorporate recent evidence, based on a critical review of the literature, to provide practical current recommendations for the prophylactic and therapeutic management of VTE in patients with cancer. Special clinical situations whose management and/or choice of currently recommended therapeutic options (low-molecular-weight heparins [LMWHs] or direct-acting oral anticoagulants [DOACs]) is controversial are included.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"2877-2901"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SEOM-GEICO Clinical Guidelines on cervical cancer (2023). SEOM-GEICO 宫颈癌临床指南(2023 年)。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-08-31 DOI: 10.1007/s12094-024-03604-3
Luis Manso, Avinash Ramchandani-Vaswani, Ignacio Romero, Luisa Sánchez-Lorenzo, María José Bermejo-Pérez, Purificación Estévez-García, Lorena Fariña-Madrid, Yolanda García García, Marta Gil-Martin, María Quindós

Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide. It is strongly associated with high-risk human papillomavirus infection. High-income countries that have implemented human papillomavirus (HPV) vaccination and screening programs have seen dramatic reductions in CC incidence, while developing countries where these programs are not available continue to experience high rates of CC deaths. In early-stage CC, the primary treatment is surgery or radiotherapy, whereas concurrent chemo-radiotherapy (CRT) remains the conventional approach in locally advanced stages until the upcoming approval of immunotherapy. The incorporation of immunotherapy in combination with chemotherapy (with or without bevacizumab) in first line and as monotherapy in second line after platinum-based chemotherapy, has significantly increased overall survival (OS) in recurrent or metastatic CC. The purpose of this guideline is to summarize the most relevant evidence in the diagnosis, treatment, and follow-up of CC and to provide evidence-based recommendations for clinical practice.

宫颈癌(CC)是全球第四大最常见癌症,也是导致妇女死亡的第四大原因。它与高危人类乳头瘤病毒感染密切相关。已实施人类乳头瘤病毒(HPV)疫苗接种和筛查计划的高收入国家的宫颈癌发病率大幅下降,而未实施这些计划的发展中国家的宫颈癌死亡率则居高不下。早期CC的主要治疗方法是手术或放疗,而在免疫疗法即将获得批准之前,局部晚期CC的常规治疗方法仍然是同步化疗和放疗(CRT)。免疫疗法与化疗(联合或不联合贝伐单抗)联合应用于一线治疗,以及在铂类化疗后作为单药应用于二线治疗,可显著提高复发或转移性CC的总生存率(OS)。本指南旨在总结CC诊断、治疗和随访方面最相关的证据,并为临床实践提供循证建议。
{"title":"SEOM-GEICO Clinical Guidelines on cervical cancer (2023).","authors":"Luis Manso, Avinash Ramchandani-Vaswani, Ignacio Romero, Luisa Sánchez-Lorenzo, María José Bermejo-Pérez, Purificación Estévez-García, Lorena Fariña-Madrid, Yolanda García García, Marta Gil-Martin, María Quindós","doi":"10.1007/s12094-024-03604-3","DOIUrl":"10.1007/s12094-024-03604-3","url":null,"abstract":"<p><p>Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide. It is strongly associated with high-risk human papillomavirus infection. High-income countries that have implemented human papillomavirus (HPV) vaccination and screening programs have seen dramatic reductions in CC incidence, while developing countries where these programs are not available continue to experience high rates of CC deaths. In early-stage CC, the primary treatment is surgery or radiotherapy, whereas concurrent chemo-radiotherapy (CRT) remains the conventional approach in locally advanced stages until the upcoming approval of immunotherapy. The incorporation of immunotherapy in combination with chemotherapy (with or without bevacizumab) in first line and as monotherapy in second line after platinum-based chemotherapy, has significantly increased overall survival (OS) in recurrent or metastatic CC. The purpose of this guideline is to summarize the most relevant evidence in the diagnosis, treatment, and follow-up of CC and to provide evidence-based recommendations for clinical practice.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"2771-2782"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023). SEOM-GEMCAD-TTD 胃癌诊断和治疗临床指南(2023 年)。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-07-18 DOI: 10.1007/s12094-024-03600-7
Fernando Rivera, Federico Longo, Marta Martín Richard, Paula Richart, Maria Alsina, Alberto Carmona, Ana Belén Custodio, Ana Fernández Montes, Javier Gallego, Tania Fleitas Kanonnikoff

Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, the incidence is lower and GC represents the tenth most frequent tumor and the seventh cause of cancer mortality. Molecular biology knowledge allowed to better profile patients for a personalized therapeutic approach. In the localized setting, the multidisciplinary team discussion is fundamental for planning the therapeutic approach. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors, and chemoradiation + surgery + adjuvant immunotherapy for the GEJ are current standards. For the metastatic setting, biomarker profiling including Her2, PD-L1, MSS status is needed. Chemotherapy in combination with checkpoint inhibitors had improved the outcomes for patients with PD-L1 expression. Her2 positive patients should receive antiHer2 therapy added to chemotherapy. We describe the different evidences and recommendations based on the literature.

胃癌(GC)是全球第五大常见癌症,其地理分布各不相同,且具有侵袭性。在西班牙,胃癌的发病率较低,是第十大常见肿瘤和第七大癌症死因。分子生物学知识使我们能够更好地对患者进行特征描述,从而采取个性化的治疗方法。在局部环境中,多学科团队讨论是规划治疗方法的基础。目前的标准是在极早期进行内窥镜切除术,对局部晚期肿瘤进行围手术期化疗,对胃食管癌进行化放疗+手术+辅助免疫治疗。对于转移性肿瘤,需要进行生物标志物分析,包括Her2、PD-L1和MSS状态。化疗联合检查点抑制剂可改善PD-L1表达患者的预后。Her2阳性患者应在化疗的基础上接受抗Her2治疗。我们介绍了基于文献的不同证据和建议。
{"title":"SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023).","authors":"Fernando Rivera, Federico Longo, Marta Martín Richard, Paula Richart, Maria Alsina, Alberto Carmona, Ana Belén Custodio, Ana Fernández Montes, Javier Gallego, Tania Fleitas Kanonnikoff","doi":"10.1007/s12094-024-03600-7","DOIUrl":"10.1007/s12094-024-03600-7","url":null,"abstract":"<p><p>Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, the incidence is lower and GC represents the tenth most frequent tumor and the seventh cause of cancer mortality. Molecular biology knowledge allowed to better profile patients for a personalized therapeutic approach. In the localized setting, the multidisciplinary team discussion is fundamental for planning the therapeutic approach. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors, and chemoradiation + surgery + adjuvant immunotherapy for the GEJ are current standards. For the metastatic setting, biomarker profiling including Her2, PD-L1, MSS status is needed. Chemotherapy in combination with checkpoint inhibitors had improved the outcomes for patients with PD-L1 expression. Her2 positive patients should receive antiHer2 therapy added to chemotherapy. We describe the different evidences and recommendations based on the literature.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"2826-2840"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141635590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distinguishing clinical and imaging characteristics of primary central nervous system lymphoma from high-grade glioma and metastatic brain tumors. 区分原发性中枢神经系统淋巴瘤与高级别胶质瘤和转移性脑肿瘤的临床和成像特征。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-31 DOI: 10.1007/s12094-024-03771-3
Qian Hu, Shenyang Zhang, Rui Xue Ma, Fengyi Lu, Qi Zhang, Jia Jing, Hafiz Khuram Raza, Shengli Li, Li Cheng, Zuohui Zhang, Lin He, Wenqing Meng, Hao Chen, Wei Chen

Objective: The purpose of this retrospective analysis was to evaluate the clinical presentations, radiological characteristics, patient outcomes, and therapeutic approaches among individuals diagnosed with primary central nervous system lymphoma (PCNSL), high-grade glioma (HGG), and metastatic brain tumors (METS).

Methods: We assembled a cohort of brain tumor patients from two medical centers, with two oncologists independently reviewing their clinical profiles. A retrospective examination of 87 PCNSL, 87 HGG, and 71 METS cases was performed to assess the aforementioned parameters.

Results: Notable variations were identified in the incidence of epileptic seizures and cognitive impairments between PCNSL and METS patients. Cerebral hemisphere involvement was predominantly observed in HGG and METS cases. PCNSL cases exhibited a higher likelihood of multiple lesions, whereas HGG showed a greater tendency for recurrence. The median survival times were established at 24.3 months for PCNSL, 44.5 months for HGG, and 27.1 months for METS patients. In PCNSL cases, the number of lesions was identified as a significant predictor of mortality (P = 0.008).

Conclusions: Our findings highlight the importance of clinical and imaging features in diagnosing PCNSL, which may present distinct features compared to HGG and METS.

研究目的这项回顾性分析旨在评估原发性中枢神经系统淋巴瘤(PCNSL)、高级别胶质瘤(HGG)和转移性脑肿瘤(METS)患者的临床表现、放射学特征、患者预后和治疗方法:我们从两个医疗中心收集了一批脑肿瘤患者,由两名肿瘤学家独立审查他们的临床资料。我们对 87 例 PCNSL、87 例 HGG 和 71 例 METS 进行了回顾性检查,以评估上述参数:结果:在 PCNSL 和 METS 患者的癫痫发作率和认知障碍方面发现了明显的差异。在HGG和METS病例中主要观察到大脑半球受累。PCNSL 病例出现多个病灶的可能性更高,而 HGG 病例则更容易复发。PCNSL 患者的中位生存时间为 24.3 个月,HGG 患者为 44.5 个月,METS 患者为 27.1 个月。在 PCNSL 病例中,病灶数量被确定为死亡率的重要预测因素(P = 0.008):我们的研究结果强调了临床和影像学特征在诊断 PCNSL 中的重要性,与 HGG 和 METS 相比,PCNSL 可能具有不同的特征。
{"title":"Distinguishing clinical and imaging characteristics of primary central nervous system lymphoma from high-grade glioma and metastatic brain tumors.","authors":"Qian Hu, Shenyang Zhang, Rui Xue Ma, Fengyi Lu, Qi Zhang, Jia Jing, Hafiz Khuram Raza, Shengli Li, Li Cheng, Zuohui Zhang, Lin He, Wenqing Meng, Hao Chen, Wei Chen","doi":"10.1007/s12094-024-03771-3","DOIUrl":"https://doi.org/10.1007/s12094-024-03771-3","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this retrospective analysis was to evaluate the clinical presentations, radiological characteristics, patient outcomes, and therapeutic approaches among individuals diagnosed with primary central nervous system lymphoma (PCNSL), high-grade glioma (HGG), and metastatic brain tumors (METS).</p><p><strong>Methods: </strong>We assembled a cohort of brain tumor patients from two medical centers, with two oncologists independently reviewing their clinical profiles. A retrospective examination of 87 PCNSL, 87 HGG, and 71 METS cases was performed to assess the aforementioned parameters.</p><p><strong>Results: </strong>Notable variations were identified in the incidence of epileptic seizures and cognitive impairments between PCNSL and METS patients. Cerebral hemisphere involvement was predominantly observed in HGG and METS cases. PCNSL cases exhibited a higher likelihood of multiple lesions, whereas HGG showed a greater tendency for recurrence. The median survival times were established at 24.3 months for PCNSL, 44.5 months for HGG, and 27.1 months for METS patients. In PCNSL cases, the number of lesions was identified as a significant predictor of mortality (P = 0.008).</p><p><strong>Conclusions: </strong>Our findings highlight the importance of clinical and imaging features in diagnosing PCNSL, which may present distinct features compared to HGG and METS.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a web-based tool for estimating individualized survival curves in glioblastoma using clinical, mRNA, and tumor microenvironment features with fusion techniques. 开发基于网络的工具,利用临床、mRNA 和肿瘤微环境特征与融合技术估算胶质母细胞瘤的个体化生存曲线。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-30 DOI: 10.1007/s12094-024-03739-3
Zunlan Zhao, Yujie Shi, Shouhang Chen, Yan Xu, Fangfang Fu, Chong Li, Xiao Zhang, Ming Li, Xiqing Li

Objective: Glioblastoma (GBM), one of the most common brain tumors, is known for its low survival rates and poor treatment responses. This study aims to create a robust predictive model that integrates multiple feature types, including clinical data, RNA expression, and tumor microenvironment data, using fusion techniques to enhance model performance.

Methods: We obtained data from the SEER database to assess the impact of nine demographic and clinical features on the survival of 58,495 GBM patients and built predictive machine learning models. Additionally, mRNA expression data from 600 GBM patients from TCGA, CGGA, and GEO were analyzed. We used Cox regression and LASSO to create a gene signature, which was compared against 13 published signatures for accuracy. Twenty-one machine learning models were applied to predict survival at multiple time points. Finally, we integrated multiple feature types using fusion techniques and developed a Shiny app to provide survival predictions for GBM patients.

Results: Using the SEER database, we constructed machine learning models based on nine clinical variables: age, gender, marital status, race, tumor site, laterality, surgery, chemotherapy, and radiation therapy. The best-performing model achieved AUC values of 0.775, 0.728, 0.692, and 0.683 for predicting survival at 6, 12, 18, and 24 months in the testing cohort. In the merged TCGA, CGGA, and GEO cohorts, we identified 11 genes to develop predictive models. These 11 genes outperformed 13 other published gene signatures in predicting the prognosis of GBM. When incorporating mRNA features, tumor microenvironment features, and clinical variables into the fusion models, the AUC values for predicting survival at 6, 12, 18, and 24 months were 0.641, 0.624, 0.655, and 0.637, respectively. A user-friendly tool for predicting the survival curve of individual GBM patients is available at https://zzubioinfo.shinyapps.io/mlGBM/ .

Conclusions: Our study provides a web-based tool that includes two modules: one for predicting survival curves using only clinical variables, and another that integrates multiple feature types for more comprehensive predictions.

目的:胶质母细胞瘤(GBM)是最常见的脑肿瘤之一,以生存率低和治疗反应差而闻名。本研究旨在利用融合技术创建一个稳健的预测模型,该模型整合了多种特征类型,包括临床数据、RNA表达和肿瘤微环境数据,以提高模型的性能:我们从 SEER 数据库中获取数据,评估了九种人口统计学和临床特征对 58495 名 GBM 患者生存期的影响,并建立了预测性机器学习模型。此外,我们还分析了来自 TCGA、CGGA 和 GEO 的 600 名 GBM 患者的 mRNA 表达数据。我们使用 Cox 回归和 LASSO 创建了一个基因特征,并将其与 13 个已发表的特征进行了准确性比较。21 个机器学习模型被用于预测多个时间点的生存率。最后,我们利用融合技术整合了多种特征类型,并开发了一款 Shiny 应用,为 GBM 患者提供生存预测:利用 SEER 数据库,我们构建了基于九个临床变量的机器学习模型:年龄、性别、婚姻状况、种族、肿瘤部位、侧位、手术、化疗和放疗。表现最好的模型在预测测试队列中 6、12、18 和 24 个月的生存率方面的 AUC 值分别为 0.775、0.728、0.692 和 0.683。在合并的TCGA、CGGA和GEO队列中,我们确定了11个基因来开发预测模型。这11个基因在预测GBM预后方面的表现优于其他13个已发表的基因特征。将 mRNA 特征、肿瘤微环境特征和临床变量纳入融合模型后,预测 6、12、18 和 24 个月生存率的 AUC 值分别为 0.641、0.624、0.655 和 0.637。用于预测个别 GBM 患者生存曲线的用户友好型工具可在 https://zzubioinfo.shinyapps.io/mlGBM/ .结论:我们的研究提供了一种基于网络的工具,其中包括两个模块:一个模块仅使用临床变量预测生存曲线,另一个模块整合了多种特征类型,可进行更全面的预测。
{"title":"Development of a web-based tool for estimating individualized survival curves in glioblastoma using clinical, mRNA, and tumor microenvironment features with fusion techniques.","authors":"Zunlan Zhao, Yujie Shi, Shouhang Chen, Yan Xu, Fangfang Fu, Chong Li, Xiao Zhang, Ming Li, Xiqing Li","doi":"10.1007/s12094-024-03739-3","DOIUrl":"https://doi.org/10.1007/s12094-024-03739-3","url":null,"abstract":"<p><strong>Objective: </strong>Glioblastoma (GBM), one of the most common brain tumors, is known for its low survival rates and poor treatment responses. This study aims to create a robust predictive model that integrates multiple feature types, including clinical data, RNA expression, and tumor microenvironment data, using fusion techniques to enhance model performance.</p><p><strong>Methods: </strong>We obtained data from the SEER database to assess the impact of nine demographic and clinical features on the survival of 58,495 GBM patients and built predictive machine learning models. Additionally, mRNA expression data from 600 GBM patients from TCGA, CGGA, and GEO were analyzed. We used Cox regression and LASSO to create a gene signature, which was compared against 13 published signatures for accuracy. Twenty-one machine learning models were applied to predict survival at multiple time points. Finally, we integrated multiple feature types using fusion techniques and developed a Shiny app to provide survival predictions for GBM patients.</p><p><strong>Results: </strong>Using the SEER database, we constructed machine learning models based on nine clinical variables: age, gender, marital status, race, tumor site, laterality, surgery, chemotherapy, and radiation therapy. The best-performing model achieved AUC values of 0.775, 0.728, 0.692, and 0.683 for predicting survival at 6, 12, 18, and 24 months in the testing cohort. In the merged TCGA, CGGA, and GEO cohorts, we identified 11 genes to develop predictive models. These 11 genes outperformed 13 other published gene signatures in predicting the prognosis of GBM. When incorporating mRNA features, tumor microenvironment features, and clinical variables into the fusion models, the AUC values for predicting survival at 6, 12, 18, and 24 months were 0.641, 0.624, 0.655, and 0.637, respectively. A user-friendly tool for predicting the survival curve of individual GBM patients is available at https://zzubioinfo.shinyapps.io/mlGBM/ .</p><p><strong>Conclusions: </strong>Our study provides a web-based tool that includes two modules: one for predicting survival curves using only clinical variables, and another that integrates multiple feature types for more comprehensive predictions.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shugoshin 1 expression in various cancers: a potential target for therapy. 舒戈欣 1 在各种癌症中的表达:潜在的治疗靶点。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-30 DOI: 10.1007/s12094-024-03749-1
Indumathi Ankathatti Narayanaswamy, Abhay Kumaraswamy Kattepur, Kalyani Raju, Venkatachalam Perumal, Ravi Ramalingam, Venkateswarlu Raavi

Shugoshin 1 (SGO1) is one of the Shugoshin (guardian spirit) family proteins, which is reported to be majorly involved in the protection of centromeres and proper segregation of chromosomes during cell division. Recent studies found that the altered expression of SGO1 is associated with various cancers and genetic disorders, and suggested as a target for therapy. In the present study, we have reviewed the available literature on SGO1 gene and protein expression in various cancer-cell lines, animal models and cancer patients, and targeting SGO1 with siRNA/shRNA. A significant increase in the expression of SGO1 mRNA and protein levels were observed in prostate, renal, lung, breast, neuroblastoma, leukemia, hepatocellular, and colon cancer-cell lines and the levels were associated with increased cellular proliferation, invasion, and metastasis. The altered SGO1 levels were observed in SGO1 knockout/haploinsufficient mice compared to wild type and the levels were associated with increased chromosome instability and tumorigenesis. Consistent with cell lines, higher SGO1 expression was also observed in tumor tissues of cancer patients compared to adjacent normal tissue and the levels were positively correlated with tumor stage, grade, size, and hormonal status. Higher SGO1 expression was related to resistance to chemotherapeutic agents and the knockdown of SGO1 increased sensitivity to those agents. Furthermore, targeting SGO1 with siRNA/shRNA reduced the expression of SGO1 and proliferation, and induced apoptosis of cancer cells. Overall, the SGO1 expression levels were significantly higher in various cancers, and targeting SGO1 with siRNA and shRNA reduced the levels of SGO1, proliferation and metastasis of cancers.

据报道,舒戈欣 1(SGO1)是舒戈欣(守护神)家族蛋白之一,主要参与细胞分裂过程中中心粒的保护和染色体的正常分离。最近的研究发现,SGO1 的表达改变与多种癌症和遗传疾病有关,并建议将其作为治疗靶点。在本研究中,我们回顾了现有文献中有关 SGO1 基因和蛋白在各种癌细胞系、动物模型和癌症患者中的表达,以及用 siRNA/shRNA 靶向 SGO1 的研究。在前列腺癌、肾癌、肺癌、乳腺癌、神经母细胞瘤、白血病、肝癌和结肠癌细胞系中,我们观察到 SGO1 mRNA 和蛋白水平的表达明显增加,而且其水平与细胞增殖、侵袭和转移的增加有关。与野生型相比,在 SGO1 基因敲除/单倍体不足的小鼠中观察到了 SGO1 水平的改变,而这一水平与染色体不稳定性和肿瘤发生的增加有关。与细胞系一致,在癌症患者的肿瘤组织中也观察到 SGO1 的表达高于邻近的正常组织,而且其水平与肿瘤分期、分级、大小和激素状态呈正相关。SGO1 的高表达与对化疗药物的耐药性有关,而 SGO1 的敲除会增加对这些药物的敏感性。此外,用 siRNA/shRNA 靶向 SGO1 可减少 SGO1 的表达和增殖,并诱导癌细胞凋亡。总之,SGO1在各种癌症中的表达水平都明显较高,而用siRNA和shRNA靶向SGO1可以降低SGO1的水平,减少癌症的增殖和转移。
{"title":"Shugoshin 1 expression in various cancers: a potential target for therapy.","authors":"Indumathi Ankathatti Narayanaswamy, Abhay Kumaraswamy Kattepur, Kalyani Raju, Venkatachalam Perumal, Ravi Ramalingam, Venkateswarlu Raavi","doi":"10.1007/s12094-024-03749-1","DOIUrl":"https://doi.org/10.1007/s12094-024-03749-1","url":null,"abstract":"<p><p>Shugoshin 1 (SGO1) is one of the Shugoshin (guardian spirit) family proteins, which is reported to be majorly involved in the protection of centromeres and proper segregation of chromosomes during cell division. Recent studies found that the altered expression of SGO1 is associated with various cancers and genetic disorders, and suggested as a target for therapy. In the present study, we have reviewed the available literature on SGO1 gene and protein expression in various cancer-cell lines, animal models and cancer patients, and targeting SGO1 with siRNA/shRNA. A significant increase in the expression of SGO1 mRNA and protein levels were observed in prostate, renal, lung, breast, neuroblastoma, leukemia, hepatocellular, and colon cancer-cell lines and the levels were associated with increased cellular proliferation, invasion, and metastasis. The altered SGO1 levels were observed in SGO1 knockout/haploinsufficient mice compared to wild type and the levels were associated with increased chromosome instability and tumorigenesis. Consistent with cell lines, higher SGO1 expression was also observed in tumor tissues of cancer patients compared to adjacent normal tissue and the levels were positively correlated with tumor stage, grade, size, and hormonal status. Higher SGO1 expression was related to resistance to chemotherapeutic agents and the knockdown of SGO1 increased sensitivity to those agents. Furthermore, targeting SGO1 with siRNA/shRNA reduced the expression of SGO1 and proliferation, and induced apoptosis of cancer cells. Overall, the SGO1 expression levels were significantly higher in various cancers, and targeting SGO1 with siRNA and shRNA reduced the levels of SGO1, proliferation and metastasis of cancers.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical & Translational Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1